From gene-sequencing to electronic health records, big data is transforming scientific discovery and healthcare. With these advances comes the promise of precision medicine—personalizing medical care based on each patient’s unique biology, genetics, and circumstances. But more data does not necessarily translate into better healthcare or scientific advances.
Through The Call to Lead campaign, Geisel seeks to grow and accelerate its research and educational programs in the biomedical data sciences—for the benefit of students, patients, and society at large.
Researcher Mike Whitfield, PhD, studies gene-to-gene communication in scleroderma, a rare and debilitating disease. His discoveries are being used to create new diagnostic technologies that can help patients find the best, most effective treatments. Whitfield is also chair of the Department of Biomedical Data Sciences at Geisel.
Related Priorities
